CCIA
LUMO

Campbell & Co Investment Adviser’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Campbell & Co Investment Adviser’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,437
Closed -$95K – 472
2017
Q2 		$95K Buy
+1,437
New +$178K 0.09% 308

Other funds holding LUMO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Campbell & Co Investment Adviser's LUMO Position: Q3 2017 in Review

Campbell & Co Investment Adviser sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2017, closing a stake of 1,437 shares — an estimated $95K sold.

Campbell & Co Investment Adviser first reported a position in LUMO in Q2 2017 and held it in 1 quarter. The position peaked at $95K in Q2 2017. 126 funds tracked by Wall St. Rank hold LUMO as of Q3 2017.

  • Campbell & Co Investment Adviser reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 1,437 Lumos Pharma, Inc. Common Stock shares in Q3 2017, an estimated $95K.
  • Campbell & Co Investment Adviser first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Lumos Pharma, Inc. Common Stock position peaked at $95K in Q2 2017.
  • 126 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2017.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2017, filed 13 Nov 2017.